Biotest (Grifols) expects sales of its drug Yimmugo in the US of 936.4 million over the next 7 years

It will launch intravenous immunoglobulin in the United States during the first quarter of 2025 1 Jul. () –

Biotest, a company of the Grifols group, foresees revenues of approximately 1,000 million dollars (930.36 million euros) from sales in the United States of intravenous immunoglobulin (Ig) Yimmugo during the next seven years, as announced this Monday by the company. blood products in a statement.

This forecast is part of the recent approval by the United States Food and Drug Administration (FDA) of this drug to treat primary immunodeficiencies.

The Catalan firm recalls that Yimmugo is the first Biotest medicine produced at the ‘Next Level’ plant in Dreieich (Germany) that will be marketed in the United States.

In this context, this plant has recently been certified by the FDA and already has approval for production and marketing in Europe, where Yimmugo has been sold since the end of 2022.

Yimmugo will be launched in the United States during the first quarter of 2025 and will be distributed by Kedrion under a seven-year agreement with Biotest, which is part of the Grifols Group’s broad distribution strategy to ensure extensive reach and availability of its Ig therapies.

He also recalled that the Grifols Group and Kedrion have a long-standing collaborative relationship.

In this way, Grifols will focus on continuing to drive the growth of its leading and consolidated intravenous and subcutaneous Ig treatments.

With Yimmugo, the group’s US portfolio will have an “additional option” to address the growing demand for Ig to treat immunodeficiencies, which occur when a part of the body’s immune system is absent or not working properly, and other diseases.

The president of Grifols’ Biopharma business unit, Roland Wandeler, said that ensuring patients receive the best possible care is at the “core” of its mission. “Our distribution strategy will allow us to take full advantage of the availability of Grifols’ premium intravenous and subcutaneous immunoglobulins throughout the United States, offering patients a wide range of effective treatments,” he added.

Following the launch of Yimmugo, considered a “key lever” in Grifols’ growth strategy in the United States, other proteins from the group will follow in this market, such as fibrinogen and trimodulin, both in an “advanced” phase of development.

Specifically, its fibrinogen concentrate would be the first approved for an acquired fibrinogen deficiency indication in the United States, while trimodulin is a polyvalent antibody composition for community-acquired pneumonia or severe community-acquired pneumonia.

“We are excited to enter this important market for the industry with Yimmugo and are committed to developing and bringing more therapies to patients in the United States in the coming years,” said Peter Janssen, CEO of Biotest AG.

Grifols shares rose 1.27% on the stock market at 12:50 p.m., to 7.96 euros.